Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that 4-(ethoxycarbophenyl) retinamide (RI) exhibited significantly lower acute, subacute, and chronic toxicity compared to other retinoids in mouse and rat models.

This study identified novel compounds as selective inhibitors of the type 1 isoenzyme of 5α-reductase, displaying promising potential for treating DHT-dependent disorders such as acne and androgenic alopecia.

This study found that patients receiving active ritlecitinib doses reported greater satisfaction with hair growth compared to placebo, with high agreement observed between clinician evaluations of scalp hair improvement and patient satisfaction through week 48.

In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.

This meta-analysis reports that 5-alpha-reductase inhibitors are associated with a 31% increased risk of depression, with varying outcomes depending on the comparator group, highlighting significant heterogeneity across studies.

This systematic review and meta-analysis found that mood stabilizers used for bipolar disorder, such as lithium, valproate, carbamazepine, and lamotrigine, resulted in varying prevalence of dermatologic side effects, with lamotrigine showing the highest rash incidence, while severe reactions were rare.

This report describes a case where a 23-year-old woman with juvenile rheumatoid arthritis developed generalized ichthyosiform eruption due to sarcoidosis after long-term use of systemic corticosteroids.

This study found that valproate sustained-release monotherapy provided effective short-term seizure control and was well tolerated in newly-diagnosed epileptic patients with partial seizures in the Gulf Cooperation Council countries.

This review discusses the complex relationship between psychotropic medications and the skin, focusing on cutaneous side effects, dermatologic uses, and psychiatric disorders with skin manifestations, but reports no new findings.

This review discusses the use of Serenoa repens for benign prostatic hyperplasia symptoms, noting similar efficacy to other treatments but highlights the need for further rigorous trials to confirm effectiveness.

This study reports that novel hexahydrobenzoquinolin compounds fully inhibited 5α-reductase activity in human genital skin fibroblasts, suggesting their potential for treating conditions like benign prostatic hyperplasia and male pattern baldness.

Some drugs can cause serious side effects, like hypoglycemia from mix-ups, skin reactions, or depression, and while penicillamine may help rheumatoid arthritis more than auranofin, it has more severe side effects.

In this prospective study, ritlecitinib effectively reduced hair loss in patients with severe alopecia areata, with 43.3% of participants achieving a 20 or lower SALT score by week 24, and showed a good midterm safety profile.

This study found that bupropion was associated with a higher risk of hair loss compared to other antidepressants, with paroxetine presenting the lowest risk.

Topiramate may help improve disruptive behaviors in children with bipolar disorder.

The researchers reported that QR678 Neo® combined with intralesional steroids significantly improved hair regrowth and patient satisfaction in treating alopecia areata compared to steroids alone.

This study reports that a 15-year-old with trichotillomania showed improvement with aripiprazole treatment, though no consensus on treatment exists in the literature.

This study found that D-004, a lipid extract from royal palm fruit, has a moderate antidepressant effect in mice, which may help treat depressive symptoms in patients with benign prostatic hyperplasia.

This study found that ritlecitinib, approved for alopecia areata in patients aged 12 and older, has an acceptable safety profile with mild to moderate side effects and no increase in serious adverse events compared to placebo.